Vascular biomarkers and digital ulcerations in systemic sclerosis: results from a randomized controlled trial of oral treprostinil (DISTOL-1) | Zendy

Christopher A. Mecoli | Zendy; Jamie Perin | Zendy; Jennifer E. Van Eyk | Zendy; Jie Wei Zhu | Zendy; Qin Fu | Zendy; Andrew G. Allmon | Zendy; Youlan Rao | Zendy; Scott L. Zeger | Zendy; Fredrick M. Wigley | Zendy; Laura K. Hummers | Zendy; Ami A. Shah | Zendy

Open Access

Vascular biomarkers and digital ulcerations in systemic sclerosis: results from a randomized controlled trial of oral treprostinil (DISTOL-1)

Author(s) -

Christopher A. Mecoli,

Jamie Perin,

Jennifer E. Van Eyk,

Jie Wei Zhu,

Qin Fu,

Andrew G. Allmon,

Youlan Rao,

Scott L. Zeger,

Fredrick M. Wigley,

Laura K. Hummers,

Ami A. Shah

Publication year - 2019

Publication title -

clinical rheumatology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.835

H-Index - 82

eISSN - 1434-9949

pISSN - 0770-3198

DOI - 10.1007/s10067-019-04863-0

Subject(s) - treprostinil , medicine , rheumatology , randomized controlled trial , scleroderma (fungus) , cardiology , physical therapy , pathology , pulmonary hypertension , inoculation

Although there is abundant evidence of vascular perturbation from studies of peripheral blood in systemic sclerosis (SSc), there are few data about the ability to use biomarkers of vascular injury and growth factors to predict vascular outcomes and response to therapy. We sought to explore the association between candidate vascular biomarkers and digital ulcerations (DU) in a clinical trial context.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research